NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 100 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 100 is a fixed-dose oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa prevents peripheral conversion and entacapone inhibits catechol O-methyltransferase to extend levodopa availability. This triple-combination approach addresses motor fluctuations in advanced Parkinson's disease.
$0.229MPart D
LOE ApproachingProduct approaches loss of exclusivity with modest Part D utilization; brand teams face imminent generic conversion and shrinking commercial opportunity.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STALEVO 100 offers limited career growth opportunity due to its LOE-approaching status and minimal linked job openings. Roles available are primarily focused on managed decline, generic transition support, or defending market share against impending generic competition.
Brand ManagerField Sales Representative
Worked on STALEVO 100 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.